NCT05320393View on ClinicalTrials.gov

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

March 30, 2022

Primary Completion Date

May 22, 2023

Study Completion Date

May 22, 2023

Conditions
Glabellar Frown Lines
Interventions
DRUG

PrabotulinumtoxinA-Xvfs

One treatment of 40 units

DRUG

OnabotulinumtoxinA

One treatment of 20 units

DRUG

PrabotulinumtoxinA-Xvfs

One treatment of 20 units

Trial Locations (1)

33431

Aesthetic Eyelid Plastic Surgery, Boca Raton

Sponsors

Lead Sponsor

Evolus, Inc.
All Listed Sponsors
collaborator

ethica Clinical Research Inc.

INDUSTRY

lead

Evolus, Inc.

INDUSTRY

NCT05320393 - Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines | Biotech Hunter | Biotech Hunter